AbbVie, renowned for its portfolio of groundbreaking treatments, has achieved a major milestone with the FDA's approval of Vyalev, a novel combination therapy aimed at providing extended movement control for patients with advanced Parkinson’s disease. The approval represents more than just a
Sage Therapeutics, a biopharmaceutical company specializing in brain health medications, finds itself at a pivotal moment. Facing financial strains and developmental hurdles, the company is taking significant steps to realign its strategy, including layoffs, leadership changes, and focusing on
Nuclera, a trailblazing biotechnology company specializing in protein expression and purification, recently raised $75 million in a fresh funding round. This significant financial boost is intended to support the commercialization and global deployment of Nuclera’s eProtein Discovery™ system. The
Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes
Lundbeck, the Danish drugmaker, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion, centering the deal around Longboard's promising experimental brain medicine, bexicaserin. This medicine is in late-stage clinical testing for treating developmental and epileptic
The approval of Bluebird bio's gene therapy, Skysona, in September 2022 by the FDA marked a significant milestone for treating cerebral adrenoleukodystrophy (CALD), a rare and fatal childhood brain disorder. Skysona's innovation generated hope for families dealing with CALD, yet recent developments
